Novo Nordisk is a Denmark-based multinational pharmaceutical company that develops and commercializes insulins for the treatment of diabetes and chronic diseases.
CIIE accelerates approval for innovative medical products
China International Import Expo accelerates approval for innovative medical products from Edwards Lifesciences, Novo Nordisk, and Boehringer Ingelheim, transforming exhibits into commercial products.
NMPA approves Novo Nordisk's Icodec-Semaglutide for type 2 diabetes
NMPA approves Novo Nordisk's Icodec-Semaglutide, the first weekly basal insulin/GLP-1RA for type 2 diabetes, offering improved glycemic control and patient benefits.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.